Uppsala, Sweden, August 31, 2016 — Oasmia Pharmaceutical AB (NASDAQ: OASM), a developer of a new generation of drugs within human and veterinary oncology has announced the appointment of Fredrik Gynnerstedt to the position of Chief Financial Officer (CFO).

Fredrik Gynnerstedt possesses 15 years’ experience in international business administration and activities. Previously, Fredrik was employed as the Director of Collaboration at Karnov Group. Prior to that role, he served as Chief Financial Officer for publicly held Bringwell AB, and as auditor and consultant at Ernst & Young. Fredrik has a Master’s degree in Business Administration from Stockholm University.

“I’m happy to join the team at Oasmia, a company currently in an exciting phase as it pursues global commercialization via its robust pipeline of pharmaceutical products,” said Fredrik Gynnerstedt. “I’m looking forward to contributing to the continued success of the Company in my new capacity as Chief Financial Officer.”

Fredrik Gynnerstedt’s employment begins on December 1, 2016 and he will be a member of Oasmia’s management team.